Implementation of cancer next-generation sequencing testing in a community hospital

被引:16
作者
Akkari, Yassmine [1 ]
Smith, Tamara [1 ]
Westfall, Jennifer [1 ]
Lupo, Stacie [1 ]
机构
[1] Legacy Hlth, Legacy Lab Serv, Dept Mol Diagnost, Portland, OR 97232 USA
来源
COLD SPRING HARBOR MOLECULAR CASE STUDIES | 2019年 / 5卷 / 03期
关键词
ASSOCIATION;
D O I
10.1101/mcs.a003707
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In the current era of personalized medicine, the field of oncology is witnessing a paradigm shift in patient care that is driving a tighter integration of genomic analysis modalities in patient care decision. This is driven by the expanding category of targeted therapies that require a broader understanding of the mutational profile of patient samples to more precisely guided personalized treatment decisions. Next-generation sequencing (NGS) has proved to be of tremendous power in detecting and characterizing a broad spectrum of activating or loss-of-function mutations across many gene targets. This power of NGS also results in significant challenges related to technical expertise, bioinformatics, computing infrastructure, laboratory practices, and integration into clinical decision-making. These challenges are particularly relevant to smaller and mid-tier hospital networks that are faced with the need to modernize their clinical practices and offer their patients access to advanced genomic technologies to improve outcomes. Adoption of such personalized medicine relies on information about a patient's cancer genome and the identification of its variants. This is best achieved using NGS. However, there are challenges to the adoption of such a complex technology and workflow, especially in smaller hospital systems. This commentary summarizes key considerations and challenges related to implementation of NGS in a community hospital setting.
引用
收藏
页数:8
相关论文
共 3 条
  • [1] Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer
    Bielski, Craig M.
    Donoghue, Mark T. A.
    Gadiya, Mayur
    Hanrahan, Aphrothiti J.
    Won, Helen H.
    Chang, Matthew T.
    Jonsson, Philip
    Penson, Alexander, V
    Gorelick, Alexander
    Harris, Christopher
    Schram, Alison M.
    Syed, Aijazuddin
    Zehir, Ahmet
    Chapman, Paul B.
    Hyman, David M.
    Solit, David B.
    Shannon, Kevin
    Chandarlapaty, Sarat
    Berger, Michael F.
    Taylor, Barry S.
    [J]. CANCER CELL, 2018, 34 (05) : 852 - +
  • [2] Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists
    Jennings, Lawrence J.
    Arcila, Maria E.
    Corless, Christopher
    Kamel-Reid, Suzanne
    Lubin, Ira M.
    Pfeifer, John
    Temple-Smolkin, Robyn L.
    Voelkerding, Karl V.
    Nikiforova, Marina N.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (03) : 341 - 365
  • [3] Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
    Lindeman, Neal I.
    Cagle, Philip T.
    Aisner, Dara L.
    Arcila, Maria E.
    Beasley, Mary Beth
    Bernicker, Eric H.
    Colasacco, Carol
    Dacic, Sanja
    Hirsch, Fred R.
    Kerr, Keith
    Kwiatkowski, David J.
    Ladanyi, Marc
    Nowak, Jan A.
    Sholl, Lynette
    Temple-Smolkin, Robyn
    Solomon, Benjamin
    Souter, Lesley H.
    Thunnissen, Erik
    Tsao, Ming S.
    Ventura, Christina B.
    Wynes, Murry W.
    Yatabe, Yasushi
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (03) : 323 - 358